Survival in an era of organ preservation: an update on laryngeal cancer in Ireland.
Head and neck cancer epidemiology
Laryngeal cancer
Laryngeal cancer incidence
Survival
T3 laryngeal cancer
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
18
04
2023
accepted:
01
06
2023
medline:
5
9
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Laryngeal cancer epidemiology has changed in recent years, with falling incidence observed internationally. Organ preservation therapies have revolutionised management, though some patients may be unsuitable and survival was noted to fall in the 2000s. This study examines trends in laryngeal cancer in Ireland. A retrospective cohort study of National Cancer Registry of Ireland data from 1994 to 2014. From a cohort of 2651, glottic disease was most common (62%, n = 1646). Incidence rose to 3.43 cases/100,000/year for 2010-2014. 5-year disease-specific survival (DSS) was 60.6% and did not change significantly over time. Overall survival (OS) for T3 disease managed with primary radiotherapy was similar to primary surgery (HR 0.98, p = 0.9). DSS for T3 disease improved with primary radiotherapy (HR 0.72, p = 0.045). Incidence of laryngeal cancer in Ireland rose despite international trends, while survival changed little. Radiotherapy improves DSS for T3 disease but does not improve OS, possibly secondary to poor organ function post-radiotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Laryngeal cancer epidemiology has changed in recent years, with falling incidence observed internationally. Organ preservation therapies have revolutionised management, though some patients may be unsuitable and survival was noted to fall in the 2000s. This study examines trends in laryngeal cancer in Ireland.
METHODS
METHODS
A retrospective cohort study of National Cancer Registry of Ireland data from 1994 to 2014.
RESULTS
RESULTS
From a cohort of 2651, glottic disease was most common (62%, n = 1646). Incidence rose to 3.43 cases/100,000/year for 2010-2014. 5-year disease-specific survival (DSS) was 60.6% and did not change significantly over time. Overall survival (OS) for T3 disease managed with primary radiotherapy was similar to primary surgery (HR 0.98, p = 0.9). DSS for T3 disease improved with primary radiotherapy (HR 0.72, p = 0.045).
CONCLUSION
CONCLUSIONS
Incidence of laryngeal cancer in Ireland rose despite international trends, while survival changed little. Radiotherapy improves DSS for T3 disease but does not improve OS, possibly secondary to poor organ function post-radiotherapy.
Identifiants
pubmed: 37326667
doi: 10.1007/s00405-023-08055-0
pii: 10.1007/s00405-023-08055-0
pmc: PMC10477096
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4587-4595Informations de copyright
© 2023. The Author(s).
Références
Joshi P, Dutta S, Chaturvedi P, Nair S (2014) Head and neck cancers in developing countries. Rambam Maimonides Med J 5(2):e0009
doi: 10.5041/RMMJ.10143
pubmed: 24808947
pmcid: 4011474
Koskinen A, Hemminki O, Försti A, Hemminki K (2022) Incidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century. PLoS ONE 17(5):e0268922
doi: 10.1371/journal.pone.0268922
pubmed: 35622857
pmcid: 9140270
Oukessou Y, Chebaatha A, Berrada O, Abada RL, Rouadi S, Roubal M et al (2022) Primary carcinoma of the larynx in females: a case series. Ann Med Surg (Lond) 78:103851
pubmed: 35734668
García-León FJ, García-Estepa R, Romero-Tabares A, Gómez-Millán BJ (2017) Treatment of advanced laryngeal cancer and quality of life. Systematic review. Acta Otorrinolaringol Esp 68(4):212–219
doi: 10.1016/j.otorri.2016.11.005
Nocini R, Molteni G, Mattiuzzi C, Lippi G (2020) Updates on larynx cancer epidemiology. Chin J Cancer Res 32(1):18–25
doi: 10.21147/j.issn.1000-9604.2020.01.03
pubmed: 32194301
pmcid: 7072014
Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE et al (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324(24):1685–1690
doi: 10.1056/NEJM199106133242402
pubmed: 2034244
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098
doi: 10.1056/NEJMoa031317
pubmed: 14645636
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF et al (2013) Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852
doi: 10.1200/JCO.2012.43.6097
pubmed: 23182993
Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF (2017) An update on larynx cancer. CA Cancer J Clin 67(1):31–50
doi: 10.3322/caac.21386
pubmed: 27898173
Obid R, Redlich M, Tomeh C (2019) The treatment of laryngeal cancer. Oral Maxillofac Surg Clin North Am 31(1):1–11
doi: 10.1016/j.coms.2018.09.001
pubmed: 30449522
Tamaki A, Miles BA, Lango M, Kowalski L, Zender CA (2018) AHNS series: do you know your guidelines? Review of current knowledge on laryngeal cancer. Head Neck 40(1):170–181
doi: 10.1002/hed.24862
pubmed: 29076227
O’Neill CB, O’Neill JP, Atoria CL, Baxi SS, Henman MC, Ganly I et al (2014) Treatment complications and survival in advanced laryngeal cancer: a population-based analysis. Laryngoscope 124(12):2707–2713
doi: 10.1002/lary.24658
pubmed: 24577936
pmcid: 4821412
Nahavandipour A, Jakobsen KK, Grønhøj C, Hebbelstrup Jensen D, Kim Schmidt Karnov K, Klitmøller Agander T et al (2019) Incidence and survival of laryngeal cancer in Denmark: a nation-wide study from 1980 to 2014. Acta Oncol 58(7):977–982
doi: 10.1080/0284186X.2019.1572923
pubmed: 30821560
Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ et al (2006) Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 116(S111):1–13
doi: 10.1097/01.mlg.0000236095.97947.26
pubmed: 16946667
Huang SH, O’Sullivan B (2017) Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol 18(7):40
doi: 10.1007/s11864-017-0484-y
pubmed: 28555375
The National Cancer Registry Board (Establishment) Order, 1991, Stat. 19/1991 (1991)
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33
doi: 10.3322/caac.21708
pubmed: 35020204
McElvaney NG (2004) Smoking ban–made in Ireland, for home use and for export. N Engl J Med 350(22):2231–2233
doi: 10.1056/NEJMp048097
pubmed: 15163770
Office CS. Census 2016 Results (2022)
Strojan P, Haigentz M, Bradford CR, Wolf GT, Hartl DM, Langendijk JA et al (2013) Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma. Oral Oncol 49(4):283–286
doi: 10.1016/j.oraloncology.2012.11.002
pubmed: 23219843
Al-Mamgani A, Navran A, Walraven I, Schreuder WH, Tesselaar MET, Klop WMC (2019) Organ-preservation (chemo)radiotherapy for T4 laryngeal and hypopharyngeal cancer: is the effort worth? Eur Arch Otorhinolaryngol 276(2):575–583
doi: 10.1007/s00405-018-5241-8
pubmed: 30564952
Patel SA, Qureshi MM, Dyer MA, Jalisi S, Grillone G, Truong MT (2019) Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer. Cancer 125(19):3367–3377
doi: 10.1002/cncr.32292
pubmed: 31206637
Eita A, Mohamed N, Rybkin A, Kang JJ, Fiasconaro M, Zhigang Z et al (2022) Outcomes for organ preservation with chemoradiation therapy for T4 Larynx and hypopharynx cancer. Laryngoscope. https://doi.org/10.1002/lary.30279
doi: 10.1002/lary.30279
pubmed: 35801573
Lee MY, Belfiglio M, Zeng J, Fleming CW, Koyfman S, Joshi NP et al (2022) Primary total laryngectomy versus organ preservation for locally advanced T3/T4a laryngeal cancer. Laryngoscope. https://doi.org/10.1002/lary.30254
doi: 10.1002/lary.30254
pubmed: 36519414
Campbell G, Glazer TA, Kimple RJ, Bruce JY (2022) Advances in organ preservation for laryngeal cancer. Curr Treat Options Oncol 23(4):594–608
doi: 10.1007/s11864-022-00945-5
pubmed: 35303749
pmcid: 9405127
Patel SG, Shah JP (2005) TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 55(4):242–258 (quiz 61-2, 64)
doi: 10.3322/canjclin.55.4.242
pubmed: 16020425
Timmermans AJ, de Gooijer CJ, Hamming-Vrieze O, Hilgers FJ, van den Brekel MW (2015) T3–T4 laryngeal cancer in The Netherlands Cancer Institute; 10-year results of the consistent application of an organ-preserving/-sacrificing protocol. Head Neck 37(10):1495–1503
doi: 10.1002/hed.23789
pubmed: 24891221
Hrelec C (2021) Management of laryngeal dysplasia and early invasive cancer. Curr Treat Options Oncol 22(10):90
doi: 10.1007/s11864-021-00881-w
pubmed: 34424405
Doornaert P, Terhaard CH, Kaanders JH (2015) Treatment of T3 laryngeal cancer in the Netherlands: a national survey. Radiat Oncol 10:134
doi: 10.1186/s13014-015-0440-6
pubmed: 26112272
pmcid: 4480981
Jones TM, De M, Foran B, Harrington K, Mortimore S (2016) Laryngeal cancer: United Kingdom National Multidisciplinary guidelines. J Laryngol Otol 130(S2):S75–S82
doi: 10.1017/S0022215116000487
pubmed: 27841116
pmcid: 4873912
Bozec A, Culié D, Poissonnet G, Dassonville O (2020) Current role of total laryngectomy in the era of organ preservation. Cancers (Basel). 12(3):584
doi: 10.3390/cancers12030584
pubmed: 32138168
pmcid: 7139381
Kim BH, Park SJ, Jeong WJ, Ahn SH (2018) Comparison of treatment outcomes for T3 glottic squamous cell carcinoma: a meta-analysis. Clin Exp Otorhinolaryngol 11(1):1–8
doi: 10.21053/ceo.2017.00717
pubmed: 29486540
pmcid: 5831661